Search academic texts

Information × Registration Number 0220U001119, 0118U003430 , R & D reports Title To improve laboratory monitoring of hemophilia patients treatment on the basis of studying the mechanisms of action of blood clotting preparations using a complex of coagulogic and global tests of hemostasis popup.stage_title Head Stasyshyn Oleksandra Vasylivna, д.мед.н. Registration Date 27-01-2020 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 Object: 25 patients with hemophilia A and 2 patients with hemophilia В in the age from 9 to 60 years, who were examined and treated at the Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (Lviv). Aim. Based on the study of the mechanisms of action of coagulation factors, to work out parameters for laboratory monitoring of hemostatic therapy in order to optimize and individualize the treatment of hemophilia patients. The study included clinical, cytological, hematologic, biochemical, general coagulological studies, and a thromboelastogram (TEG). We used hematological analyzer Micros 60 No. 814773, biochemical analyzer Pentra -400, No. 807P4-2012, semi-automatic coagulometer Helena-C4, No. C4-2561, thromboelastograph TEG 5000® Haemoscope Corp., Niles IL, No. S091204020. According to the clinical evaluation of the hemostatic action of bypassing agents (rFVIIa and APCC) in the hemophilia patients with inhibitors, their high efficiency is established. Patients' response to rFVIIa treatment and changes in thromboelastogram (TEG) are individual. The clinical effect correlates with the normalization of TEG parameters 10-15 min after rFVIIa administration. All patients receiving APCC had a clinical effect regardless of its dose . The control of APCC therapy can be performed using TEG at intervals of 30 min to 3 h according to the results of the parameters of the properties of the clot at different stages of its formation and stabilization. TEG can predict the patient's response to rFVIIa and APCC administration. In the prophylactic treatment of hemophilia patients with concizumab or fituziran, the bleeding frequency significantly decreased, indicating the clinical efficacy of the drugs. The low informativeness of TEG for the control of concizumab therapy in patients with severe hemophilia A with inhibitor was revealed. Regardless of the type of hemophilia and the presence of inhibitors, control of treatment with fituziran is possible using TEG parameters characterizing the density, quality, stability, and hemostatic clot capabilities. The mechanism of action and the effect of the action of fituziran, rFVIIa and APCC are reflected in the TEG at the final stage of the blood clotting process - clot formation. TEG may be a reliable method of control the therapy of these agents Product Description popup.authors Дзісь Р.П. Красівська В.В. Семерак М.М. Тушницький О.М. popup.nrat_date 2020-04-02 Close